详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Epigenetic Therapy Promotes the Ratio of Th1/Th17 Lineage to Reverse Immune Evasion and Treat Leukemia Relapse Post-allogeneic Stem Cell Transplantation in Non-APL AML Patients.

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Sichuan Provincial People's Hospital, Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu, China. [2]Penn State Cancer Institute, Penn State University College of Medicine, Hershey, PA, United States.

出处：

DOI：

ISSN：

关键词： epigenetic regimen non-APL AML transplant relapse immune evasion Th1/Th17

摘要：

To reverse the early-stage relapse post-hematopoietic stem cell transplantation, we investigated the safety and efficacy of a new epigenetic regimen (chidamide and decitabine plus thymalfasin simultaneously) on acute myeloid leukemia patients (excluding acute promyelocytic leukemia). Twenty-four patients were enrolled in this observational study during April 2015 to May 2018. The most common adverse event was reversible CTCAE grade 2 thrombocytopenia (20/24). Strikingly, all 24 patients had response to this epigenetic regimen accompanied with decreased measurable residual disease. The overall survival rate is 79.2% (19/24), with a relapse-free survival rate of 79.2% (19/24). During this regimen treatment, Th1 cells and CD3+CD4-CD8+T cells increased, and Th17 cells decreased gradually. The status of high Th1 and low Th17 cells was still observed on the 3rd month after discontinuation of this regimen. Interestingly, the significantly elevated ratio of Th1/Th17 seemed to reflect the treatment-related immune effect, which may be a valuable marker to be monitored in the early-relapse stage for evaluating the efficacy and prognosis.Copyright © 2021 Xi, Jingying, Chenglong, Hong, Rong, Xiaodong, Chunsen and Xiaobing.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2020]版：

大类 | 3 区生物学

小类 | 4 区生化与分子生物学

最新[2023]版：

大类 | 3 区生物学

小类 | 3 区生化与分子生物学

第一作者：

第一作者机构： [1]Sichuan Provincial People's Hospital, Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu, China.

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Epigenetic Therapy Promotes the Ratio of Th1/Th17 Lineage to Reverse Immune Evasion and Treat Leukemia Relapse Post-allogeneic Stem Cell Transplantation in Non-APL AML Patients [2]Interleukin-10 deficiency impairs regulatory T cell-derived neuropilin-1 functions and promotes Th1 and Th17 immunity. [3]Publisher Correction: Landscape of B cell immunity and related immune evasion in human cancers. [4]HMMR triggers immune evasion of hepatocellular carcinoma by inactivation of phagocyte killing [5]β-Catenin induces transcriptional expression of PD-L1 to promote glioblastoma immune evasion. [6]The tumor-intrinsic role of the m6A reader YTHDF2 in regulating immune evasion [7]Disruption of Ferroptosis Inhibition and Immune Evasion with Tumor-Activatable Prodrug for Boosted Photodynamic/Chemotherapy Eradication of Drug-Resistant Tumors [8]Integrative analysis of genomic and epigenomic regulation reveals miRNA mediated tumor heterogeneity and immune evasion in lower grade glioma [9]CD276-dependent efferocytosis by tumor-associated macrophages promotes immune evasion in bladder cancer [10]Landscape of B cell immunity and related immune evasion in human cancers.